World's Best Scientists 2026 revealed!
VIEW LIST
Paul Lorigan

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 93 10638 9988 1015 968 553 71189

Paul Lorigan publications per year

The chart shows the history of publications by Paul Lorigan between 1989 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Paul Lorigan published across 37 years, from 1989 to 2025, averaging 18.4 papers a year. Output peaked at 88 publications in 2023. 53 of the 680 publications appeared in the last two years.

No. of publications
20 40 60 80
Bar chart. Horizontal axis: year, 1989 to 2025. Vertical axis: number of publications, 0 to 88. Peak 88 publications in 2023. 1989: 2 publications 1990: 0 publications 1991: 0 publications 1992: 0 publications 1993: 0 publications 1994: 1 publication 1995: 4 publications 1996: 7 publications 1997: 10 publications 1998: 8 publications 1999: 8 publications 2000: 14 publications 2001: 3 publications 2002: 12 publications 2003: 10 publications 2004: 8 publications 2005: 16 publications 2006: 14 publications 2007: 13 publications 2008: 14 publications 2009: 27 publications 2010: 20 publications 2011: 33 publications 2012: 28 publications 2013: 22 publications 2014: 27 publications 2015: 27 publications 2016: 37 publications 2017: 28 publications 2018: 32 publications 2019: 16 publications 2020: 27 publications 2021: 35 publications 2022: 36 publications 2023: 88 publications 2024: 29 publications 2025: 24 publications
1989 2025

680 publications in total across all disciplines

View publications per year as a table
Paul Lorigan: publications per year, 1989 to 2025
Year Publications
1989 2
1990 0
1991 0
1992 0
1993 0
1994 1
1995 4
1996 7
1997 10
1998 8
1999 8
2000 14
2001 3
2002 12
2003 10
2004 8
2005 16
2006 14
2007 13
2008 14
2009 27
2010 20
2011 33
2012 28
2013 22
2014 27
2015 27
2016 37
2017 28
2018 32
2019 16
2020 27
2021 35
2022 36
2023 88
2024 29
2025 24
Total 680
Download as CSV

Paul Lorigan publications per year - data summary

  • Paul Lorigan, a Medicine scholar from University of Manchester, has 680 publications recorded across 37 years, from 1989 to 2025.
  • The oldest publication on record dates to 1989 and the most recent to 2025.
  • The most productive year is 2023, with 88 publications.
  • The least productive year with any output is 1994, with 1 publication.
  • 4 of the 37 years in the span carry no publications at all (1990, 1991, 1992 and 1993).
  • The rate of publication averages 18.4 papers per year over the whole span, or 20.6 per year counting only the 33 years with at least one publication.
  • The last 5 years on the chart (2021-2025) hold 212 publications, 31% of the career total.
  • Split into equal eras - 1989-2001: 57 publications (4.4 per year); 2002-2014: 244 publications (18.8 per year); 2015-2025: 379 publications (34.5 per year).
  • Comparing the opening and closing eras, the overall trend of publication is rising.

Paul Lorigan publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Paul Lorigan sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 541–560 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 553 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537 553
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Paul Lorigan publication distribution in Medicine in 2026 - data summary

  • The chart plots the publication count of all 20,134 Medicine scientists ranked by Research.com in 2026, grouped into 86 ranges running from 101–120 to 1,796+ publications.
  • Paul Lorigan, a Medicine scholar from University of Manchester, records 553 publications - the 66th percentile of the discipline.
  • 66% of ranked Medicine scientists score the same or lower than Paul Lorigan, and about 34% score higher.
  • The median of the discipline falls in the 441–460 publications range, and Paul Lorigan ranks above the median.
  • The most crowded range is 341–360 publications, holding 922 scientists (5% of the field).
  • 64% of the field sits in the lowest quarter of the value range (up to 521–540 publications), so the distribution is heavily right-skewed and high scores are rare.
  • The final bar has no upper bound: it groups every scientist with 1,796 publications or more, 100 scientists in all (<1% of the field).

Paul Lorigan D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Paul Lorigan sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 92–93 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839 93
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Paul Lorigan D-index placement in Medicine in 2026 - data summary

  • The chart plots the discipline H-index (D-index) of all 20,134 Medicine scientists ranked by Research.com in 2026, grouped into 75 ranges running from 70–71 to 217+ D-Index.
  • Paul Lorigan, a Medicine scholar from University of Manchester, records 93 D-Index - the 47th percentile of the discipline.
  • 47% of ranked Medicine scientists score the same or lower than Paul Lorigan, and about 53% score higher.
  • The median of the discipline falls in the 94–95 D-Index range, and Paul Lorigan ranks below the median.
  • The most crowded range is 82–83 D-Index, holding 1,027 scientists (5% of the field).
  • 70% of the field sits in the lowest quarter of the value range (up to 106–107 D-Index), so the distribution is heavily right-skewed and high scores are rare.
  • The final bar has no upper bound: it groups every scientist with 217 D-Index or more, 98 scientists in all (<1% of the field).

Overview

Paul Lorigan is affiliated with the University of Manchester in the United Kingdom. Their research spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on Oncology, Molecular Biology, and Immunology. They have also contributed notably to Epidemiology and Cancer Research.

The scientist's main research topics include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Colorectal Cancer Treatments and Studies
  • Nonmelanoma Skin Cancer Studies

Frequent publication venues for their work are:

  • European Journal of Cancer
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer
  • British Journal of Dermatology

Frequent co-authors collaborating with Paul Lorigan include:

  • Paolo A. Ascierto
  • Georgina V. Long
  • Mario Mandalà
  • James Larkin
  • Caroline Robert

Selected recent papers authored or co-authored by Paul Lorigan include:

  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo, 2020, JAMA Oncology
  • Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma, 2022, Nature Medicine
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022, 2022, European Journal of Cancer
  • Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial, 2020, Journal of Clinical Oncology

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Sandra P D'Angelo;James Larkin;Jeffrey A Sosman;Celeste Lebbé

  • Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

    James Larkin;David Minor;Sandra D'Angelo;Bart Neyns

  • Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

    A. Le Cesne;J.Y. Blay;I. Judson;A. Van Oosterom

  • Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

    Martin Reck;Alexander Luft;Aleksandra Szczesna;Libor Havel

  • Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

    Corinne Faivre-Finn;Michael Snee;Linda Ashcroft;Wiebke Appel

  • Revised U.K. guidelines for the management of cutaneous melanoma 2010.

    J.R. Marsden;J.A. Newton-Bishop;L. Burrows;M. Cook

  • Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

    Maria R. Girotti;Malin Pedersen;Berta Sanchez-Laorden;Amaya Viros

  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

    Alexander M.M. Eggermont;Michal Kicinski;Christian U. Blank;Mario Mandala

  • Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.

    Natalie J Ives;Rebecca L Stowe;Paul C Lorigan;Keith Wheatley

  • Revised UK guidelines for the management of cutaneous melanoma 2010

    J R Marsden;J A Newton-Bishop;L Burrows;M Cook

Frequent Co-Authors

James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Nick Thatcher
Nick Thatcher University of Manchester
Fiona H Blackhall
Fiona H Blackhall University of Manchester
Georgina V. Long
Georgina V. Long University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Mark R. Middleton
Mark R. Middleton University of Oxford
Claus Garbe
Claus Garbe University of Tübingen
Matteo S. Carlino
Matteo S. Carlino University of Sydney

External Links

Personal website of Paul Lorigan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As medical careers evolve, many students look to online education for flexibility and affordability. There is a growing range of online healthcare degrees that open doors to rewarding roles outside traditional physician paths. For example, many aspiring healthcare professionals consider how much does it cost to become a medical coder. Medical coding is an entry point for those interested in healthcare administration and can be pursued entirely online at a lower cost compared to clinical degrees.

Nursing remains a top choice for those who want to work directly with patients. If budget is a concern, students often research cheap np programs to become Nurse Practitioners or explore cheapest bsn programs online for Bachelor of Science in Nursing options. Even advanced roles are accessible, such as obtaining a terminal degree through cheapest online dnp programs for a Doctor of Nursing Practice.

With diverse and affordable online pathways, students can tailor their educational journeys to fit both their career goals and financial needs.

Best Scientists Citing Paul Lorigan

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 288

Jedd D. Wolchok

Jedd D. Wolchok

Cornell University

Publications: 249

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 230

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 225

Caroline Robert

Caroline Robert

University of Paris-Saclay

Publications: 205

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 197

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 191

Reinhard Dummer

Reinhard Dummer

University of Zurich

Publications: 171

Alexander M. Menzies

Alexander M. Menzies

University of Sydney

Publications: 164

Michael A. Postow

Michael A. Postow

Memorial Sloan Kettering Cancer Center

Publications: 164

Antoni Ribas

Antoni Ribas

University of California, Los Angeles

Publications: 162

F. Stephen Hodi

F. Stephen Hodi

Harvard University

Publications: 156

Richard F. Kefford

Richard F. Kefford

Macquarie University

Publications: 155

Alexander M.M. Eggermont

Alexander M.M. Eggermont

Institut Gustave Roussy

Publications: 151

John F. Thompson

John F. Thompson

University of Sydney

Publications: 147

Claus Garbe

Claus Garbe

University of Tübingen

Publications: 142

Trending Scientists

Aleksey Yerokhin

Aleksey Yerokhin

University of Manchester

Antonio Salas

Antonio Salas

University of Santiago de Compostela

Muhammad M. Khellah

Muhammad M. Khellah

Intel (United States)

Yongpan Liu

Yongpan Liu

Tsinghua University

J. G. Cramer

J. G. Cramer

University of Washington

Julia M.L. Brotherton

Julia M.L. Brotherton

University of Melbourne

Grace M. Aldrovandi

Grace M. Aldrovandi

University of California, Los Angeles

Emma Sprooten

Emma Sprooten

Radboud University

Paul Declerck

Paul Declerck

KU Leuven

W. J. Pledger

W. J. Pledger

University of South Florida

Francesca Granucci

Francesca Granucci

University of Milano-Bicocca

David E. Wentworth

David E. Wentworth

Centers for Disease Control and Prevention

Tova Milo

Tova Milo

Tel Aviv University

Andreas Bender

Andreas Bender

University of Cambridge

Ricard Gavaldà

Ricard Gavaldà

Universitat Politècnica de Catalunya

Til Stürmer

Til Stürmer

University of North Carolina at Chapel Hill

Related Medicine Rankings & Guides

2027 Best Occupational Therapy Programs

2027 Best Occupational Therapy Programs
2027 Fastest Online RN to MSN (No ADN Required) Bridge Programs

2027 Fastest Online RN to MSN (No ADN Required) Bridge Programs
2027 Medical Lab Tech Programs Online: Best Schools

2027 Medical Lab Tech Programs Online: Best Schools
2026 Easiest Accelerated BSN Programs to Get Into

2026 Easiest Accelerated BSN Programs to Get Into
2027 Best Online Respiratory Therapy Programs

2027 Best Online Respiratory Therapy Programs
2027 Most Affordable Online Accelerated Nursing Programs With High Graduation Rate

2027 Most Affordable Online Accelerated Nursing Programs With High Graduation Rate
September 2027 Best Online Certificate Programs in Medical Billing & Coding Programs

September 2027 Best Online Certificate Programs in Medical Billing & Coding Programs
2027 Most Affordable Healthcare Administration Degrees Online

2027 Most Affordable Healthcare Administration Degrees Online
2027 Best Online Associate in Physical Therapy Assistant Programs

2027 Best Online Associate in Physical Therapy Assistant Programs
2027 Best Online Associate Science in Nursing (ASN) Programs

2027 Best Online Associate Science in Nursing (ASN) Programs
2027 Best Online CAHME-Accredited MHA Programs

2027 Best Online CAHME-Accredited MHA Programs
2027 Most Affordable Online LPN to RN Degree Programs

2027 Most Affordable Online LPN to RN Degree Programs
2027 Most Affordable Online Medical Assistant Programs

2027 Most Affordable Online Medical Assistant Programs
September 2027 Best Online Physician Assistant Master’s Programs

September 2027 Best Online Physician Assistant Master’s Programs
2027 Easiest RN-to-BSN Online Programs

2027 Easiest RN-to-BSN Online Programs
2027 Most Affordable Online DNP Programs

2027 Most Affordable Online DNP Programs
2027 Most Affordable Online FNP Programs

2027 Most Affordable Online FNP Programs
2027 Best Online MSN Family Nurse Practitioner Programs

2027 Best Online MSN Family Nurse Practitioner Programs
2027 Fastest Online Exercise Science Degree Programs

2027 Fastest Online Exercise Science Degree Programs
2027 Best Online Associate in Health Sciences

2027 Best Online Associate in Health Sciences
2027 Best Nurse Practitioner Programs in Utah – Accredited Schools Online & Campus

2027 Best Nurse Practitioner Programs in Utah – Accredited Schools Online & Campus

Recently Published Articles

2027 Most Affordable Online Nursing Programs: Tuition, Coursework & Credit Requirements

2027 Most Affordable Online Nursing Programs: Tuition, Coursework & Credit Requirements
2027 Different Types of Psychology Degrees and Their Salaries

2027 Different Types of Psychology Degrees and Their Salaries
2027 Is Behavioral Health Science a Hard Major? What Students Should Know

2027 Is Behavioral Health Science a Hard Major? What Students Should Know
2027 How to Become a High School History Teacher in New York: Requirements & Certification

2027 How to Become a High School History Teacher in New York: Requirements & Certification
2027 Fastest Online Emergency Management Bachelor's Degree Programs You Can Finish in 3 Years or Less

2027 Fastest Online Emergency Management Bachelor's Degree Programs You Can Finish in 3 Years or Less
2027 Most Affordable Online Information Technology Degrees

2027 Most Affordable Online Information Technology Degrees
2027 How to Become a Nutritionist in New Mexico

2027 How to Become a Nutritionist in New Mexico
2027 Most In-Demand Human Services Master's Specializations

2027 Most In-Demand Human Services Master's Specializations
2027 Is a 2-Year Accounting Degree Worth It: Accelerated Bachelor's ROI & Time Trade-Offs

2027 Is a 2-Year Accounting Degree Worth It: Accelerated Bachelor's ROI & Time Trade-Offs
2027 Fastest Online Graduate Certificate Programs in Data Analytics

2027 Fastest Online Graduate Certificate Programs in Data Analytics
2027 Aerospace Engineering Degree: Requirements, Job Prospects & Salary

2027 Aerospace Engineering Degree: Requirements, Job Prospects & Salary
2027 Best Careers After a PharmD

2027 Best Careers After a PharmD
2027 Is a Graphic Design Degree Worth It?

2027 Is a Graphic Design Degree Worth It?
2027 Licensing Exams Required After Completing a Child Development Degree Program

2027 Licensing Exams Required After Completing a Child Development Degree Program
2027 Can You Get Into an Audio & Music Program with a Low GPA? Admission Chances & Workarounds

2027 Can You Get Into an Audio & Music Program with a Low GPA? Admission Chances & Workarounds
2027 Highest Level of Respiratory Care Therapy Degree You Can Achieve: Academic Progression Explained

2027 Highest Level of Respiratory Care Therapy Degree You Can Achieve: Academic Progression Explained
2027 How to Become a BCBA in Pittsburgh, PA: Education Requirements & Certification

2027 How to Become a BCBA in Pittsburgh, PA: Education Requirements & Certification
2027 Competency-Based Online Artificial Intelligence Master's Degrees

2027 Competency-Based Online Artificial Intelligence Master's Degrees
2027 How to Become a Human Resources Assistant

2027 How to Become a Human Resources Assistant
2027 Cinematography Degree Salary by Industry: Where Graduates Earn the Most

2027 Cinematography Degree Salary by Industry: Where Graduates Earn the Most
2027 Self-Paced AI Bachelor's Degree Programs

2027 Self-Paced AI Bachelor's Degree Programs